Shares of Athersys, which have nearly doubled in the past 3 months, should keep their momentum as a number of data points concerning the company's regenerative medicine treatments roll in, says Gil Van Bokkelen, CEO of Athersys. Van Bokkelen says the company's lead drug MultiStem is entering into a number of late stage clinical trials across a number of illnesses. He also says the company is making huge strides with patents in Japan and has successfully raised enough cash to carry it forward.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Video: This One Mathematical Concept Can Make You a Millionaire

Video: This One Mathematical Concept Can Make You a Millionaire

AAP Exclusive: Nvidia is Tied to Crypto and That's Bad

AAP Exclusive: Nvidia is Tied to Crypto and That's Bad

Video: Abercrombie & Fitch Shares Surged 57% So Far This Year

Video: Abercrombie & Fitch Shares Surged 57% So Far This Year

Video: Why It's Key to Invest in Stocks Even If You Have Student Loan Debt

Video: Why It's Key to Invest in Stocks Even If You Have Student Loan Debt

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs